AAPL   320.41 (-0.45%)
MSFT   182.33 (-0.27%)
FB   228.33 (-1.55%)
GOOGL   1,429.52 (-0.37%)
AMZN   2,459.65 (-0.46%)
CGC   16.37 (-0.67%)
BABA   211.78 (+2.52%)
MU   46.13 (-0.45%)
AMD   52.43 (-2.26%)
T   30.87 (-0.23%)
ACB   14.22 (+0.85%)
F   5.92 (+0.85%)
GILD   73.16 (-2.66%)
NFLX   422.75 (-0.74%)
BAC   24.97 (+1.46%)
BA   154.40 (+1.99%)
AAPL   320.41 (-0.45%)
MSFT   182.33 (-0.27%)
FB   228.33 (-1.55%)
GOOGL   1,429.52 (-0.37%)
AMZN   2,459.65 (-0.46%)
CGC   16.37 (-0.67%)
BABA   211.78 (+2.52%)
MU   46.13 (-0.45%)
AMD   52.43 (-2.26%)
T   30.87 (-0.23%)
ACB   14.22 (+0.85%)
F   5.92 (+0.85%)
GILD   73.16 (-2.66%)
NFLX   422.75 (-0.74%)
BAC   24.97 (+1.46%)
BA   154.40 (+1.99%)
AAPL   320.41 (-0.45%)
MSFT   182.33 (-0.27%)
FB   228.33 (-1.55%)
GOOGL   1,429.52 (-0.37%)
AMZN   2,459.65 (-0.46%)
CGC   16.37 (-0.67%)
BABA   211.78 (+2.52%)
MU   46.13 (-0.45%)
AMD   52.43 (-2.26%)
T   30.87 (-0.23%)
ACB   14.22 (+0.85%)
F   5.92 (+0.85%)
GILD   73.16 (-2.66%)
NFLX   422.75 (-0.74%)
BAC   24.97 (+1.46%)
BA   154.40 (+1.99%)
AAPL   320.41 (-0.45%)
MSFT   182.33 (-0.27%)
FB   228.33 (-1.55%)
GOOGL   1,429.52 (-0.37%)
AMZN   2,459.65 (-0.46%)
CGC   16.37 (-0.67%)
BABA   211.78 (+2.52%)
MU   46.13 (-0.45%)
AMD   52.43 (-2.26%)
T   30.87 (-0.23%)
ACB   14.22 (+0.85%)
F   5.92 (+0.85%)
GILD   73.16 (-2.66%)
NFLX   422.75 (-0.74%)
BAC   24.97 (+1.46%)
BA   154.40 (+1.99%)
Log in

NASDAQ:CYTKCytokinetics Stock Price, Forecast & News

$21.24
+0.34 (+1.63 %)
(As of 06/2/2020 12:56 PM ET)
Add
Compare
Today's Range
$20.35
Now: $21.24
$21.29
50-Day Range
$13.55
MA: $17.75
$22.22
52-Week Range
$7.72
Now: $21.24
$23.04
Volume6,261 shs
Average Volume1.07 million shs
Market Capitalization$1.26 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.41
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274, a novel cardiac myosin inhibitor, which is in Phase I clinical trial for the potential treatment of hypertrophic cardiomyopathy; and AMG 594, a novel cardiac troponin activator that is in Phase I clinical trial. The company has strategic alliances with Amgen Inc. and Astellas Pharma Inc. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.
Read More
Cytokinetics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.60 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYTK
CUSIPN/A
Phone650-624-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$26.87 million
Book Value($0.19) per share

Profitability

Net Income$-121,690,000.00
Net Margins-592.61%
Return on Equity-10,351.99%

Miscellaneous

Employees130
Market Cap$1.26 billion
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive CYTK News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.

Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions

How has Cytokinetics' stock been impacted by COVID-19 (Coronavirus)?

Cytokinetics' stock was trading at $12.03 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CYTK stock has increased by 76.6% and is now trading at $21.24. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cytokinetics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cytokinetics.

When is Cytokinetics' next earnings date?

Cytokinetics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Cytokinetics.

How were Cytokinetics' earnings last quarter?

Cytokinetics, Inc. (NASDAQ:CYTK) released its earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.50) by $0.16. The biopharmaceutical company earned $3.83 million during the quarter, compared to analyst estimates of $4.92 million. Cytokinetics had a negative net margin of 592.61% and a negative return on equity of 10,351.99%. View Cytokinetics' earnings history.

What price target have analysts set for CYTK?

7 analysts have issued twelve-month price targets for Cytokinetics' stock. Their forecasts range from $20.00 to $35.00. On average, they anticipate Cytokinetics' share price to reach $26.43 in the next year. This suggests a possible upside of 24.4% from the stock's current price. View analysts' price targets for Cytokinetics.

Has Cytokinetics been receiving favorable news coverage?

News headlines about CYTK stock have trended very positive this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cytokinetics earned a media sentiment score of 3.5 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutCytokinetics.

Are investors shorting Cytokinetics?

Cytokinetics saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 7,800,000 shares, a decline of 8.6% from the April 30th total of 8,530,000 shares. Based on an average daily volume of 1,010,000 shares, the short-interest ratio is presently 7.7 days. Approximately 14.4% of the shares of the stock are short sold. View Cytokinetics' Current Options Chain.

Who are some of Cytokinetics' key competitors?

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Amgen (AMGN), Novavax (NVAX), Inovio Pharmaceuticals (INO), Geron (GERN), TherapeuticsMD (TXMD), Gilead Sciences (GILD) and Immunomedics (IMMU).

Who are Cytokinetics' key executives?

Cytokinetics' management team includes the following people:
  • Mr. Robert I. Blum, CEO, Pres & Director (Age 55)
  • Mr. Ching W. Jaw, Sr. VP & CFO (Age 56)
  • Dr. Andrew A. Wolff, Sr. VP & Chief Medical Officer (Age 64)
  • Dr. Fady Ibraham Malik, Exec. VP of R&D (Age 55)
  • Dr. Bradley Paul Morgan, Sr. VP of Research & Non-Clinical Devel. (Age 59)

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.35%), Wasatch Advisors Inc. (5.05%), State Street Corp (4.52%), Foresite Capital Management IV LLC (3.66%), Two Sigma Advisers LP (1.13%) and Bank of New York Mellon Corp (1.04%). Company insiders that own Cytokinetics stock include Bvf Partners L P/Il, Fady Ibraham Malik, Robert I Blum, Santo J Costa, Value Fund L P Biotechnology and Wendall Wierenga. View institutional ownership trends for Cytokinetics.

Which major investors are selling Cytokinetics stock?

CYTK stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Foresite Capital Management IV LLC, Federated Hermes Inc., Two Sigma Investments LP, Pinnacle Associates Ltd., UBS Group AG, Arizona State Retirement System, and Bank of New York Mellon Corp. Company insiders that have sold Cytokinetics company stock in the last year include Bvf Partners L P/Il, Fady Ibraham Malik, Robert I Blum, Santo J Costa, and Wendall Wierenga. View insider buying and selling activity for Cytokinetics.

Which major investors are buying Cytokinetics stock?

CYTK stock was purchased by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Burrage Capital Management LLC, Atom Investors LP, JPMorgan Chase & Co., BNP Paribas Arbitrage SA, Two Sigma Advisers LP, State Street Corp, and Assenagon Asset Management S.A.. Company insiders that have bought Cytokinetics stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology. View insider buying and selling activity for Cytokinetics.

How do I buy shares of Cytokinetics?

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cytokinetics' stock price today?

One share of CYTK stock can currently be purchased for approximately $21.24.

How big of a company is Cytokinetics?

Cytokinetics has a market capitalization of $1.26 billion and generates $26.87 million in revenue each year. The biopharmaceutical company earns $-121,690,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Cytokinetics employs 130 workers across the globe.

What is Cytokinetics' official website?

The official website for Cytokinetics is www.cytokinetics.com.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.